[Federal Register Volume 85, Number 155 (Tuesday, August 11, 2020)]
[Notices]
[Page 48563]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-17438]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-701]


Bulk Manufacturer of Controlled Substances Application: Purisys, 
LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Purisys, LLC applied to be registered as a bulk manufacturer 
of the following basic class(es) of controlled substances: Lysergic 
acid diethylamide and Pentobarbital.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before October 13, 
2020.

ADDRESS: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on July 15, 2020, Purisys, LLC, 1550 Olympic Drive, 
Athens, Georgia 30601-1602, applied to be registered as a bulk 
manufacturer of the following basic class(es) of controlled substances:

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide.............     7315  I
Pentobarbital..........................     2270  II
------------------------------------------------------------------------

    The company plans to manufacture the above-listed controlled 
substances as analytical reference standards and clinical trial 
material for distribution to its customers. No other activities for 
these drug codes are authorized for this registration.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-17438 Filed 8-10-20; 8:45 am]
BILLING CODE P